Deoxycholic acid and selenium metabolite methylselenol exert common and distinct effects on cell cycle, apoptosis, and MAP kinase pathway in HCT116 human colon cancer cells

Nutrition and Cancer

Volumn 62, Issue 1, 2010, Pages 85-92

  Zeng, Huawei ^a   Botnen, James H ^a   Briske Anderson, Mary ^a  

^a GRAND FORKS HUMAN NUTRITION RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEOXYCHOLIC ACID; METHYLSELENOL; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; MITOGEN ACTIVATED PROTEIN KINASE KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE P38; SELENIUM DERIVATIVE; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL STRAIN HCT116; COLON CARCINOGENESIS; CONTROLLED STUDY; DRUG EFFECT; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; SIGNAL TRANSDUCTION;

APOPTOSIS; CELL CYCLE; COLONIC NEOPLASMS; DEOXYCHOLIC ACID; ENZYME ACTIVATION; G1 PHASE; G2 PHASE; HCT116 CELLS; HUMANS; METHANOL; MITOGEN-ACTIVATED PROTEIN KINASES; ORGANOSELENIUM COMPOUNDS; S PHASE; SIGNAL TRANSDUCTION;

EID: 74249094907     PISSN: 01635581     EISSN: None     Source Type: Journal    
DOI: 10.1080/01635580903191551     Document Type: Article

References (38)

1. Bayerdorffer E, Mannes GA, Richter WO, Ochsenkuhn T, Wiebecke B, et al.: Paumgartner G. Increased serum deoxycholic acid levels in men with colorectal adenomas. Gastroenterology 104, 145-151, 1993.
2. Reddy BS and Wynder EL: Metabolic epidemiology of colon cancer: fecal bile acids and neutral sterols in colon cancer patients and patients with adenomatous polyps. Cancer 39, 2533-2539, 1977.
3. Hori T, Matsumoto K, Sakaitani Y, Sato M, and Morotomi M: Effect of dietary deoxycholic acid and cholesterol on fecal steroid concentration and its impact on the colonic crypt cell proliferation in azoxymethane-treated rats. Cancer Lett 124, 79-84,1998.
4. Potten CS, O'Connor PJ, and Winton DJ: A possible explanation for the differential cancer incidence in the intestine, based on distribution of the cytotoxic effects of carcinogens in the murine large bowel. Carcinogenesis 13, 2305-2312, 1992.
5. Park H-S, Goodlad RA, and Wright NA: Crypt fission in the small intestine and colon: a mechanism for the emergence of G6PD locus-mutated crypts after treatment with mutagens. Am J Pathol 147, 1416-1427, 1995.
6. Qiao D, Stratagouleas ED, and Martinez JD:Activation and role of mitogenactivated protein kinase in deoxycholic acid-induced apoptosis. Carcinogenesis 22, 35-41, 2001.
7. Bernstein C, Bernstein H, Garewal H, Dinning P, Jabi R, et al.: A bile acid-induced apoptosis assay for colon cancer risk and associated quality control studies. Cancer Res 59, 2353-2357, 1999.
8. Whanger PD: Selenium and its relationship to cancer: an update. Br J Nutr 91, 11-28, 2004.
9. Ip C: Lessons from basic research in selenium and cancer prevention. J Nutr 128, 1845-1854, 1998.
10. Combs GF Jr, Clark LC, and Turnbull BW: Analysis of cancer prevention by selenium. Biofactors 14, 153-159, 2001.
11. Clark LC, Combs GF Jr., Turnbull BW, Slate EH, Chalker DK, et al: Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 276, 1957-1963, 1996.
12. Combs GF Jr. and Gray WP: Chemopreventive agents: selenium. Pharmacol Ther 79, 179-192, 1998.
13. Ganther HE: Seleniummetabolism, selenoproteins and mechanisms of cancer prevention: complexities with thioredoxin reductase. Carcinogenesis 20, 1657-1666, 1999.
14. Davis CD, Zeng H, and Finley JW: Selenium-enriched broccoli decreases intestinal tumorigenesis in multiple intestinal neoplasia mice. J Nutr 132, 307-309, 2002.
15. Zeng H, Briske-Anderson M, Idso JP, and Hunt CD: The selenium metabolite methylselenol inhibits the migration and invasion potential of HT1080 tumor cells. J Nutr 136, 1528-1532, 2006.
16. Jenkins GJ, D'Souza FR, Suzen SH, Eltahir ZS, James SA, et al.: Deoxycholic acid at neutral and acid pH, is genotoxic to oesophageal cells through the induction of ROS: the potential role of anti-oxidants in Barrett's oesophagus. Carcinogenesis 28, 136-142, 2007.
17. RisioM, LipkinM, Newmark H, Yang K, Rossini FP, et al.: Apoptosis, cell replication, and Western-style diet induced tumorigenesis in mouse colon. Cancer Res 56, 4910-4916, 1996.
18. Johnson GL and Lapadat R: Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 298, 1911-1912. 2002.
19. Licato LL and Brenner DA: Analysis of signaling protein kinases in human colon or colorectal carcinomas. Dig Dis Sci 43, 1454-1464, 1998.
20. Hoshino R, Chatani Y, Yamori T, Tsuruo T, Oka H, et al.: Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogne 18, 813-822, 1999.
21. Sebolt-Leopold JS, Dudley DT, Herrera R, Van Becelaere K, Wiland A, et al: Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med 5, 810-816, 1999.
22. Chen TR: In situ detection of mycoplasma contamination in cell cultures by fluorescent Hoechst 33258 stain. Exp Cell Res 104, 255-262, 1977.
23. Jiang C, Wang Z, Ganther H, and Lu J: Caspases as key executors of methyl selenium-induced apoptosis (anoikis) of DU-145 prostate cancer cells. Cancer Res 61, 3062-3070, 2001.
24. Frisch SM and Francis H: Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 124, 619-626, 1994.
25. American Cancer Society: Cancer Facts and Figures. Atlanta, GA: ACS, p. 4, 2000.
26. Bernstein C, Bernstein H, Garewal H, Dinning P, Jabi R, et al.: A bile acid-induced apoptosis assay for colon cancer risk and associated quality control studies. Cancer Res 59, 2353-2357, 1999.
27. Weinberg DS and Strom BL: Screening for colon cancer: a reviewof current and future strategies. Semin Oncol 22, 433-447, 1995.
28. Riegler M, FeilW, Lindroth J, andWong M: MIPSY. Real-time morphometry to quantify the time course of rapid epithelial restitution. Pathol Res Pract 188, 443-448, 1992.
29. Miki K, Xu M, Gupta A, Ba Y, Tan Y, et al.: Methioninase cancer gene therapy with selenomethionine as suicide prodrug substrate. Cancer Res 61, 6805-6810, 2001.
30. Wang Z, Jiang C, and Lu J: Induction of caspase-mediate apoptosis and cell-cycle G1 arrest by selenium metabolite methylselenol. Mol Carcinog 34, 113-120, 2002.
31. Spallholz JE, Palace VP, and ReidTW:Methioninase and selenomethionine but not Se-methylselenocysteine generate methylselenol and superoxide in an in vitro chemiluminescent assay: implications for the nutritional carcinostatic activity of selenoamino acids. Biochem Pharmacol 67, 547-554, 2004.
32. Esaki N, Tanaka H, Uemura S, Suzuki T, and Soda K: Catalytic action of Lmethionine gamma-lyase on selenomethionine and selenols. Biochemistry 18, 407-410, 1979.
33. Kim A, Jung JY, Son M, Lee SH, Lim JS, et al.: Long exposure of noncytotoxic concentrations of methylselenol suppresses the invasive potential of B16F10 melanoma. Oncol Rep 20, 557-565, 2008.
34. Reddy BS, Rivenson A, El-Bayoumy K, Upadhyaya P, Pittman B, et al.: Chemoprevention of colon cancer by organoselenium compounds and impact of high- or low-fat diets. J Natl Cancer Inst 89, 506-512, 1997.
35. Widmann C, Gibson S, Jarpe MB, and Johnson GL: Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. Physiol Rev 79, 143-180, 1999.
36. Wang X, Martindale JL, Liu Y, and Holbrook NJ. The cellular response to oxidative stress: Influences of mitogen-activated protein kinase signaling pathways on cell survival. Biochem J 333, 291-300, 1998.
37. Yang GH, Jarvis BB, Chung YJ, and Pestka JJ: Apoptosis induction by the satratoxins and other trichothecene mycotoxins: relationship to ERK, p38 MAPK, and SAPK/JNK activation. Toxicol Appl Pharmacol 164, 149-160, 2000.
38. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, et al.: Effect of selenium and vitamin E on risk of prostate cancer and other cancers. JAMA 301, 39-51, 2009.